Microsaic Systems plc (LON:MSYS), the developer of chip-based mass spectrometry (“MS”) instruments designed to improve the efficiency of pharmaceutical R&D, is pleased to announce the appointment of Peter Grant MA
Microsaic Systems’ Glenn Tracey discusses the research agreement with a global biopharma partner, the meaning of a biopharmaceutical, the biologics market and why they are seeing the need for in-process mass spectrometry for biologics in this exclusive interview with DirectorsTalk
Microsaic Systems plc (LON:MSYS) CEO Glenn Tracey joins DirectorsTalk to discuss the signing of a research agreement with a global partner in biopharma. Glenn provides us with some background to
Microsaic Systems plc (LON:MSYS), the developer of chip-based mass spectrometry instruments, announces that it has signed a research agreement extending its collaboration with a long standing global partner in the
Microsaic Systems’ Glenn Tracey discusses his position as CEO, mass detection, what makes their technology different, the business model and what we should look forward to in the near-future in this exclusive interview with DirectorsTalk
Microsaic Systems Plc (LON:MSYS) CEO Glenn Tracey talks to DirectorsTalk about his new role, what mass detection is and its uses, the business model and what investors should be looking
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
